515 results on '"Montero, Alberto J"'
Search Results
2. NSABP FB-10: a phase Ib/II trial evaluating ado-trastuzumab emtansine (T-DM1) with neratinib in women with metastatic HER2-positive breast cancer
3. Radiomic predicts early response to CDK4/6 inhibitors in hormone receptor positive metastatic breast cancer
4. Racial disparities in breast cancer treatment patterns and treatment related adverse events
5. Adjuvant Therapy in Breast Cancer Patients With Microscopic Residual Disease
6. Building Quality from the Ground Up in a Cancer Center
7. Abstract 12012: Adverse Social Determinants of Health Are Associated With Increased Risk of Uncontrolled Hypertension Among Cancer Patients in Rural Georgia: A Prospective Cohort Study
8. Adverse social determinants of health elevate uncontrolled hypertension risk: a cardio-oncology prospective cohort study.
9. Real-World Outcomes of Everolimus and Exemestane for the Treatment of Metastatic Hormone Receptor-Positive Breast Cancer in Patients Previously Treated With CDK4/6 Inhibitors
10. Adjuvant trastuzumab with or without chemotherapy in stage 1 pT1N0 HER2+ breast cancer: a National Cancer Database analysis
11. PET/CT Variants and Pitfalls in Breast Cancers
12. Neoadjuvant Endocrine Therapy as an Alternative to Neoadjuvant Chemotherapy Among Hormone Receptor-Positive Breast Cancer Patients: Pathologic and Surgical Outcomes
13. ASO Author Reflections: Decisions, Decisions: Neoadjuvant Chemotherapy, Neoadjuvant Endocrine Therapy, or Primary Surgery?
14. Real-world Outcomes of Cyclin-dependent Kinase Inhibitors Continued Beyond First Disease Progression in Hormone Receptor-positive Metastatic Breast Cancer
15. Building Quality from the Ground Up in a Cancer Center
16. Allostatic Load/Chronic Stress and Cardiovascular Outcomes in Patients Diagnosed With Breast, Lung, or Colorectal Cancer.
17. Giredestrant for Estrogen Receptor–Positive, HER2-Negative, Previously Treated Advanced Breast Cancer: Results From the Randomized, Phase II acelERA Breast Cancer Study.
18. Venous thromboembolism in breast cancer patients receiving cyclin‐dependent kinase inhibitors
19. Supplementary Table S1 from Phase II Clinical Trial of Pembrolizumab and Chemotherapy Reveals Distinct Transcriptomic Profiles by Radiologic Response in Metastatic Triple-Negative Breast Cancer
20. Supplementary Figure S5 from Phase II Clinical Trial of Pembrolizumab and Chemotherapy Reveals Distinct Transcriptomic Profiles by Radiologic Response in Metastatic Triple-Negative Breast Cancer
21. Data from Phase II Clinical Trial of Pembrolizumab and Chemotherapy Reveals Distinct Transcriptomic Profiles by Radiologic Response in Metastatic Triple-Negative Breast Cancer
22. Glembatumumab vedotin for patients with metastatic, gpNMB overexpressing, triple-negative breast cancer (“METRIC”): a randomized multicenter study
23. Phase 2 Trial of Induction Gemcitabine, Oxaliplatin, and Cetuximab Followed by Selective Capecitabine-Based Chemoradiation in Patients With Borderline Resectable or Unresectable Locally Advanced Pancreatic Cancer
24. ASO Visual Abstract: Neoadjuvant Endocrine Therapy as an Alternative to Neoadjuvant Chemotherapy Among Hormone Receptor Positive Breast Cancer Patients—Pathologic and Surgical Outcomes
25. Phase II Clinical Trial of Pembrolizumab and Chemotherapy Reveals Distinct Transcriptomic Profiles by Radiologic Response in Metastatic Triple-Negative Breast Cancer
26. Validation of the PREDICT Prognostication Tool in US Patients With Breast Cancer
27. Estimating the overall survival benefit of adjuvant chemo‐endocrine therapy in women over age 50 with pT1‐2N0 early stage breast cancer and 21‐gene recurrence score ≥26: A National Cancer Database analysis
28. Social Determinants of Health Data Improve the Prediction of Cardiac Outcomes in Females with Breast Cancer
29. Real-world clinical outcomes and toxicity in metastatic breast cancer patients treated with palbociclib and endocrine therapy
30. Longitudinal Effects of Adjuvant Endocrine Therapy on the Quality of Life of Post-menopausal Women with Non-metastatic ER+ Breast Cancer: A Systematic Review
31. Thirty-Day Unplanned Hospital Readmissions in Patients With Cancer and the Impact of Social Determinants of Health: A Machine Learning Approach
32. Management of Neuroendocrine Breast Carcinoma (NEBC): Review of Literature.
33. A novel cardiovascular disease risk score for prediction of atherosclerotic disease events in men with prostate cancer.
34. Individual-level social determinants of health and allostatic load/chronic toxic stress in men with prostate cancer.
35. Cost Effectiveness and Financial Toxicity in New Cancer Therapies
36. Value Assessment Frameworks in the United States: A Call for Patient Engagement
37. Adjuvant chemotherapy is associated with an overall survival benefit regardless of age in ER+/HER2- breast cancer pts with 1-3 positive nodes and oncotype DX recurrence score 20 to 25: an NCDB analysis
38. Figure S1 from A Phase I Clinical, Pharmacokinetic, and Pharmacodynamic Study of Weekly or Every Three Week Ixabepilone and Daily Sunitinib in Patients with Advanced Solid Tumors
39. Abstract GS3-01: GS3-01 EMERALD phase 3 trial of elacestrant versus standard of care endocrine therapy in patients with ER+/HER2- metastatic breast cancer: Updated results by duration of prior CDK4/6i in metastatic setting
40. Abstract P1-04-04: A multiomic approach to the identification of immune signatures of anti-PD1/PDL1 therapy responders in metastatic triple negative breast cancer: new implications in the role of helper T-cell and B-cell interplay
41. Modeling the COVID Pandemic: Do Delays in Surgery Justify Using Stereotactic Radiation to Treat Low-Risk Early Stage Non–Small Cell Lung Cancer?
42. Myeloid-Derived Suppressor Cells in Cancer
43. Allostatic load and cardiovascular outcomes in males with prostate cancer
44. Improved Clinical Outcomes Associated With Vitamin D Supplementation During Adjuvant Chemotherapy in Patients With HER2+ Nonmetastatic Breast Cancer
45. Impact of tissue-based genomic profiling on clinical decision making in the management of patients with metastatic breast cancer at academic centers
46. Sex differences in adults with acute myeloid leukemia and the impact of sex on overall survival
47. Racial Differences in Chronic Stress/Allostatic Load Variation Due to Androgen Deprivation Therapy in Prostate Cancer
48. Elacestrant (oral selective estrogen receptor degrader) Versus Standard Endocrine Therapy for Estrogen Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer: Results From the Randomized Phase III EMERALD Trial
49. Survival in elderly patients with breast cancer with and without autoimmune disease.
50. Cost-effectiveness analysis of 1st through 3rd line sequential targeted therapy in HER2-positive metastatic breast cancer in the United States
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.